Prescribing, Consent and Cosmetic Practice
- In short: Cosmetic injecting has often drifted toward consumer-shaped service models, even though the work remains regulated as healthcare.
- The Guidelines for registered health practitioners who perform non-surgical cosmetic procedures, published in June 2025 and commencing in September 2025, restate long-standing duties around prescribing, consent and oversight.
- Their purpose is to make those duties more visible across a rapidly expanding sector.
- As expectations sharpen, gaps in assessment, prescribing or stock management may draw professional scrutiny.
Though practice culture often casts non-surgical cosmetic procedures in retail terms, they have long been governed by a clinical regulatory framework. As more consumer-facing models emerged, clinics increasingly came to be styled as consumer environments. Consultations in many settings remain brief exchanges. And prescription-only medicines continue, in some services, to be handled through retail-style workflows rather than clinical ones. The regulatory foundations never shifted, but the sector’s momentum increasingly sat uncomfortably alongside them.
The Guidelines for registered health practitioners who perform non-surgical cosmetic procedures (2025) (The Cosmetic Procedures Practice Guidelines), which commence in September 2025, bring those foundations back into view. Issued under s 39 of the Health Practitioner Regulation National Law (as in force in each state and territory) and admissible under s 41, they do not create new offences. Instead, they clarify long-standing expectations around prescribing, consent and aftercare. They also make professional accountability more visible within a sector that has sometimes blurred the line between healthcare delivery and consumer-focused service models.
The shift toward clearer expectations is not without cause. The 2022 Independent Review of Cosmetic Surgery exposed patterns of complications that were no longer seen as isolated, as well as inconsistent escalation pathways, limited psychological screening and prescribing practices that relied on photographs or text-based exchanges. The Review made plain how a consumer-facing model had in many instances overshadowed fundamental clinical duties.
“The 2022 Independent Review of Cosmetic Surgery exposed patterns of complications that were no longer seen as isolated.”
The Practice Guidelines respond directly to these concerns. They restate those duties within a clearer and more enforceable framework, emphasising what responsible practitioners have always understood: that injectables are regulated medicines requiring clinical judgment, not lifestyle products supplied through commercial convenience.
The Practice Guidelines position non-surgical cosmetic work firmly within core clinical tasks: proper consultation, meaningful consent, structured aftercare, clinical oversight and appropriate prescribing. They operate alongside a wider set of regulatory obligations, including the Poisons Standard, the Therapeutic Goods Act 1989 (Cth), state and territory medicines legislation and the Australian Consumer Law (ACL).
“The Practice Guidelines do not create new offences. They clarify long-standing expectations around prescribing, consent and aftercare.”
Their effect is cumulative. They offer a clearer benchmark for professional conduct and are admissible in disciplinary proceedings. They also reinforce a simple proposition: cosmetic injecting is a form of healthcare, even when delivered in commercial settings.
The Poisons Standard, made under s 52D of the Therapeutic Goods Act 1989 (Cth), classifies medicines and other scheduled substances. The Therapeutic Goods Act governs the approval, supply and advertising of therapeutic goods. States and territories then give effect to these classifications through their own medicines and poisons legislation. Other jurisdictions use different terminology—such as New South Wales’ “Schedule 4D” or Victoria and Tasmania’s “drugs of dependence”—but the practical implications are similar: breaches tend to draw both statutory and professional attention.
Under these state and territory frameworks, only certain people and entities may lawfully possess Schedule 4 medicines as stock. A substance authority is the licence that allows a clinic to do so. These authorities are issued and enforced through Queensland Health’s medicines and poisons regulatory framework.
“In Queensland, a clinic may only hold Schedule 4 medicines as stock if it has the relevant authority under the Medicines and Poisons Act 2019 (Qld).”
In Queensland, a clinic may only hold Schedule 4 medicines as stock if it has the relevant authority under the Medicines and Poisons Act 2019 (Qld). Nurse-led clinics relying on remote prescribers must therefore use dispensed, patient-specific medicines rather than bulk stock. Some agents, particularly local anaesthetics, are classified as restricted drugs of dependency, triggering additional storage and record-keeping requirements.
These obligations are not new, but they were often pushed to the periphery by the consumer-driven models that developed around them. The Practice Guidelines make these obligations harder to overlook.
The Practice Guidelines draw together what responsible practice has long required: a genuine consultation, meaningful consent, structured aftercare and accountable service delivery.
A prescription must follow an in-person or real-time video consultation. Photographs, questionnaires or text-based exchanges cannot stand in for direct assessment. Prescribers must explore motivation, assess suitability and remain alert to psychological needs, referring where concerns arise. In Queensland, these expectations sit beneath both the MPA offence provisions and the National Law.
“Consent remains a dialogue rather than a document.”
Where the person is under 18, there must be a comprehensive clinical assessment, clear documentation of why treatment is appropriate, and at least a seven-day cooling-off period before any procedure. For nurses, the assessment must be undertaken by a Registered Nurse (RN) or Nurse Practitioner (NP) rather than an Enrolled Nurse (EN), reflecting the limitations on EN scope of practice under the Practice Guidelines.
Consent remains a dialogue rather than a document. Regulators look for evidence that a substantive discussion occurred and that the person understood the material risks.
“A person who has not been warned of the risk of blindness cannot be said to have provided informed consent.”
A person who has not been warned of the risk of blindness cannot be said to have provided informed consent. Notes that reflect the substance of the conversation—questions asked, explanations offered, understanding demonstrated—have become an essential part of safe practice.
The Practice Guidelines apply nationally, but medicines and poisons regulation remains jurisdiction-specific.
In Queensland, only authorised prescribers – in practice, medical practitioners and nurse practitioners – may purchase Schedule 4 medicines as stock and hold ‘exclusive or joint custody and control’ unless a clinic holds a substance authority.
Other jurisdictions use different terminology—such as New South Wales’ “Schedule 4D” or Victoria and Tasmania’s “drugs of dependence”—but the practical implications are similar: breaches of medicines and poisons legislation tend to draw both statutory and professional attention.
Registered nurses may administer injectables within an appropriate governance framework. Enrolled nurses face more defined prerequisites – at least one year full-time practice post-registration, a further year in a related area such as dermatology or surgery, and relevant education – and they remain restricted from very high-risk injection zones and limited in other high-risk areas unless the prescriber or an RN is immediately on site.
Medical practitioners retain responsibility for prescribing and for the clinical systems that support it. Administration may be performed by other practitioners, but accountability for prescribing decisions and oversight cannot be transferred. Remote prescribers remain responsible for the systems, decisions and outcomes of the clinics they support.
The Practice Guidelines sit within a wider lattice of obligations. The National Law governs professional conduct. State medicines legislation regulates possession and administration. The Therapeutic Goods Act prohibits advertising of prescription-only medicines, while the ACL regulates representations about services and outcomes. Infection-control frameworks and corporate governance structures sit alongside these.
Separate guidance also applies to advertising: Ahpra’s Guidelines for advertising higher risk non-surgical cosmetic procedures (2025) (Cosmetic Advertising Guidelines) address how higher-risk procedures may be promoted.
“No single instrument captures the whole. Together, they reveal the regulatory environment in which cosmetic injecting genuinely operates.”
No single instrument captures the whole. Together, they reveal the regulatory environment in which cosmetic injecting genuinely operates.
The Practice Guidelines do not resolve every tension between healthcare and consumer culture, but they narrow the gap. Clinics will need more structured consultation pathways, clearer screening processes, robust stock management and dependable follow-up. Patients will notice longer discussions, cooling-off periods and more deliberate aftercare.